<DOC>
	<DOC>NCT02314273</DOC>
	<brief_summary>The goal of this clinical research study is to find out if rhIL-11（Interleukin 11） may increase the platelet count in Childhood patients with acute lymphocytic leukemia (ALL) who develop low platelet counts while receiving standard CAT（cyclophosphamide+Cytosine arabinoside+mercaptopurine，7d） therapy.</brief_summary>
	<brief_title>Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL</brief_title>
	<detailed_description>Group A：patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80,000/mL Group B：control group</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Pancytopenia</mesh_term>
	<mesh_term>Oprelvekin</mesh_term>
	<criteria>new diagnosis of ALL TBIL≤34umol/L，Cr≤120umol/L，a normal EF age ＜18 years patients with uncontrolled infection patients with Acute congestive heart failure or chronicity cardiorespiratory functional defect or serious cardiac arrhythmias</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>